FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097996957> ?p ?o ?g. }

• W3097996957 endingPage "672" @default.
• W3097996957 startingPage "658" @default.
• W3097996957 abstract "Objective Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in combination with low-dose cytarabine (LDAC). Data Sources: PubMed and relevant congress abstracts were searched using the term “glasdegib”. In addition, based on our experience with glasdegib, we considered treatment aspects of particular relevance to pharmacists and advanced practitioners. Data Summary: In a randomized phase II study, the combination of glasdegib plus LDAC demonstrated superior overall survival versus LDAC alone (hazard ratio 0.51, 80% confidence interval 0.39–0.67, p = 0.0004). The trial reported adverse events (AEs) of special relevance for older patients, such as hematologic events, gastrointestinal toxicity, and fatigue, as well as AEs associated with Hh-pathway inhibitors (alopecia, muscle spasms, dysgeusia). Educating patients about typical AEs can facilitate adherence as well as early AE identification and proactive management. For LDAC, which is a long-established therapy in AML, various stages of delivery need consideration, with attention to individual circumstances. Practical measures such as dispensing a longer supply can reduce the number of return clinic visits, providing a meaningful difference for many patients. Conclusions Pharmacists and advanced practitioners play important roles in treatment with glasdegib plus LDAC. Ultimately, framing plans for treatment delivery within the individual circumstances of each patient may enable them to stay on therapy longer, giving them the greatest potential to achieve benefit." @default.
• W3097996957 created "2020-11-23" @default.
• W3097996957 creator A5028167880 @default.
• W3097996957 creator A5029187559 @default.
• W3097996957 creator A5037555811 @default.
• W3097996957 creator A5042986170 @default.
• W3097996957 creator A5043447747 @default.
• W3097996957 creator A5049387929 @default.
• W3097996957 creator A5051795460 @default.
• W3097996957 creator A5073695862 @default.
• W3097996957 creator A5079772081 @default.
• W3097996957 creator A5041614452 @default.
• W3097996957 date "2020-11-20" @default.
• W3097996957 modified "2023-09-27" @default.
• W3097996957 title "Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists" @default.
• W3097996957 cites W1556454749 @default.
• W3097996957 cites W1600365609 @default.
• W3097996957 cites W1916873495 @default.
• W3097996957 cites W2044292287 @default.
• W3097996957 cites W2054439285 @default.
• W3097996957 cites W2068556430 @default.
• W3097996957 cites W2091744902 @default.
• W3097996957 cites W2106084333 @default.
• W3097996957 cites W2160968219 @default.
• W3097996957 cites W2171874387 @default.
• W3097996957 cites W2321738781 @default.
• W3097996957 cites W2486839133 @default.
• W3097996957 cites W2491660866 @default.
• W3097996957 cites W2502718344 @default.
• W3097996957 cites W2673478615 @default.
• W3097996957 cites W2770907544 @default.
• W3097996957 cites W2790655004 @default.
• W3097996957 cites W2831592302 @default.
• W3097996957 cites W2883176590 @default.
• W3097996957 cites W2903900815 @default.
• W3097996957 cites W2904382086 @default.
• W3097996957 cites W2905344869 @default.
• W3097996957 cites W2910449916 @default.
• W3097996957 cites W2913364338 @default.
• W3097996957 cites W2913397271 @default.
• W3097996957 cites W2944553601 @default.
• W3097996957 cites W2949897224 @default.
• W3097996957 cites W2971500428 @default.
• W3097996957 cites W2972868802 @default.
• W3097996957 cites W3013447738 @default.
• W3097996957 doi "https://doi.org/10.1177/1078155220973737" @default.
• W3097996957 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8008421" @default.
• W3097996957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33215562" @default.
• W3097996957 hasPublicationYear "2020" @default.
• W3097996957 type Work @default.
• W3097996957 sameAs 3097996957 @default.
• W3097996957 citedByCount "4" @default.
• W3097996957 countsByYear W30979969572021 @default.
• W3097996957 countsByYear W30979969572023 @default.
• W3097996957 crossrefType "journal-article" @default.
• W3097996957 hasAuthorship W3097996957A5028167880 @default.
• W3097996957 hasAuthorship W3097996957A5029187559 @default.
• W3097996957 hasAuthorship W3097996957A5037555811 @default.
• W3097996957 hasAuthorship W3097996957A5041614452 @default.
• W3097996957 hasAuthorship W3097996957A5042986170 @default.
• W3097996957 hasAuthorship W3097996957A5043447747 @default.
• W3097996957 hasAuthorship W3097996957A5049387929 @default.
• W3097996957 hasAuthorship W3097996957A5051795460 @default.
• W3097996957 hasAuthorship W3097996957A5073695862 @default.
• W3097996957 hasAuthorship W3097996957A5079772081 @default.
• W3097996957 hasBestOaLocation W30979969571 @default.
• W3097996957 hasConcept C104863432 @default.
• W3097996957 hasConcept C126322002 @default.
• W3097996957 hasConcept C143998085 @default.
• W3097996957 hasConcept C177713679 @default.
• W3097996957 hasConcept C197934379 @default.
• W3097996957 hasConcept C2777054765 @default.
• W3097996957 hasConcept C2778041864 @default.
• W3097996957 hasConcept C2778375690 @default.
• W3097996957 hasConcept C2778729363 @default.
• W3097996957 hasConcept C2779457091 @default.
• W3097996957 hasConcept C2780670349 @default.
• W3097996957 hasConcept C512399662 @default.
• W3097996957 hasConcept C71924100 @default.
• W3097996957 hasConceptScore W3097996957C104863432 @default.
• W3097996957 hasConceptScore W3097996957C126322002 @default.
• W3097996957 hasConceptScore W3097996957C143998085 @default.
• W3097996957 hasConceptScore W3097996957C177713679 @default.
• W3097996957 hasConceptScore W3097996957C197934379 @default.
• W3097996957 hasConceptScore W3097996957C2777054765 @default.
• W3097996957 hasConceptScore W3097996957C2778041864 @default.
• W3097996957 hasConceptScore W3097996957C2778375690 @default.
• W3097996957 hasConceptScore W3097996957C2778729363 @default.
• W3097996957 hasConceptScore W3097996957C2779457091 @default.
• W3097996957 hasConceptScore W3097996957C2780670349 @default.
• W3097996957 hasConceptScore W3097996957C512399662 @default.
• W3097996957 hasConceptScore W3097996957C71924100 @default.
• W3097996957 hasFunder F4320307765 @default.
• W3097996957 hasIssue "3" @default.
• W3097996957 hasLocation W30979969571 @default.
• W3097996957 hasLocation W30979969572 @default.
• W3097996957 hasOpenAccess W3097996957 @default.
• W3097996957 hasPrimaryLocation W30979969571 @default.

• next